BiotechTube
Home/Alector/Giacomo Salvadore, M.D.
GS

Giacomo Salvadore, M.D.

Chief Medical Officer

Alector

Therapeutic Areas

Neurodegenerative DiseasesNeurologyImmunology

Alector Pipeline

DrugIndicationPhase
AL001 (Latozinemab)Frontotemporal Dementia with progranulin mutation (FTD-GRN)Phase 3
AL101 / GSK4527226Early Alzheimer's DiseasePhase 2
AL002Early Alzheimer's DiseasePhase 2
AL001FTD with C9orf72 mutation (FTD-C9orf72)Phase 2
AL101Parkinson's DiseasePreclinical
AL137-ABCAlzheimer's DiseasePreclinical
AL050-ABCParkinson's Disease, Gaucher Disease, Lewy Body DementiaPreclinical
AL064-ABC / ADP064-ABCAlzheimer's Disease, Frontotemporal DementiaResearch

Leadership Team at Alector

AR
Arnon Rosenthal, Ph.D.
Co-Founder, Chief Executive Officer, and Director
NB
Neil Berkley, M.S., M.B.A.
Chief Financial Officer and Chief Business Officer
View full Alector profile